Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

You have to read some real dross to come up with something good. From the other place.

SHANKSY1 - 11 Nov'04 - 10:51 - 7344 of 7516

Having read over the inpharma article again from yesterday, the following paragraph stuck out and this is my own speculation / reading between the lines of what may come to pass.

Now taking that Custom Pharmaceutical is UK based and the following products are mentioned in this article; SWOLLO, TABWRAP AND WAFERTAB.

Reading between the lines, Custom may be used to support Wyeth and Perrigo's markets in Europe & the US (and maybe Africa, etc).

Does this insight give us an indication that either another Pharma out there may be looking at WAFERTAB or are Wyeth going to add this to their License Option.?

The next thing was the mention of TABWRAP licensed by Perrigo. I went and had a look at the Perrigo website for the latest news. As pasted in below, Perrigo have entered into a product development, license and manufacturing agreement with Bentley Pharmaceuticals.
I also went back to the CS Brokers Note and re-read the Perrigo Section as a means of cross referencing this info.

Questions / Speculation;
1/ Will BPRG /HH Tabwrap machines be located in Bentley Pharmaceuticals Subsidiaries in Spain?
2/ If so, are they locating / relocating manufacturing in Spain due to cost reasons or is this part of the Perrigo Strategy to open up the European and other markets?
3/ Is it a combination of both (2).
4/ Film supply, if this required, will it come from the UK or will another 'LOCUM' be required in Europe to support and reduce end product costs / maintain margins.?
5/ Would film casting be located onsite as indicated in the BN?

All of the above is open to debate and no more than me reading into possible future scenarios from information already available from BPRG and on the net.


INPHARMA ARTICLE; EXTRACT; 10TH NOV. 2004
Nigel Richardson, chairman of Custom, noted that contract manufacturing of medicines is becoming a fiercely competitive global business, and companies must invest in state of the art facilities like Moulescoombe in order to stay competitive. And this is more the case than ever now that new low cost pharmaceutical manufacturing capacity is coming on line from China and India.

Dosage forms like SWOLLO, TABWRAP and WAFERTAB which we can see could have a serious impact on the traditional pharmaceutical manufacturing cost model could offer Custom a significant competitive advantage in our contract manufacturing core business, he said.

Hind said the film casting line should be operational by May 2005.

http://www.inpharma.com/news/news-ng.asp?n=55993-bioprogress-taps-cmo


BENTLEY PHARMACEUTICALS AND PERRIGO COMPANY
ANNOUNCE MULTI-PRODUCT COLLABORATION

Exeter, NH and Allegan, MI, Nov. 3, 2004

Bentley Pharmaceuticals, Inc. (NYSE: BNT), a technology-based specialty pharmaceuticals and drug delivery company, and Perrigo Company (Nasdaq: PRGO), the nations largest manufacturer of over-the-counter (OTC) pharmaceutical and nutritional products for the store brand market, announced today that they have entered into a product development, license and manufacturing agreement. Perrigo has agreed to co-develop, market and sell in the U.S., and potentially other markets, selected products produced by Bentleys active pharmaceutical ingredients (API) manufacturing facility and finished dosage forms produced by Bentleys manufacturing subsidiary, Laboratorios Belmac.

Under the agreement, Abbreviated New Drug Applications (ANDAs) for the co-developed products will be submitted by Perrigo to the U.S. Food and Drug Administration (FDA). The two companies have identified certain prescription drugs for co-development and commercialization that are no longer under patent protection or are soon to lose patent protection in the U.S.

The specific products have not been disclosed for competitive reasons.
James R. Murphy, Bentleys Chairman and CEO, commented, Moving into the U.S. market is a key step in our growth strategy that will position us in the
largest pharmaceutical market in the world, while maximizing production and
sales from our manufacturing facilities in Spain. Worldwide annual sales of each branded drug selected by Perrigo and Bentley are in the multi-billion dollar range according to IMS data. Perrigo, which announced its intentions in late 2003 to expand into the generic prescription marketplace, is the national leader in the supply of OTC pharmaceuticals to retail drug, food and mass merchandise chains under their own labels in the U.S., and we are delighted to have partnered with such a well established and respected company.

Mark P. Olesnavage, Executive Vice President and General Manager,
Perrigo Pharmaceuticals, stated, Perrigo is pleased with the opportunity to
partner with Bentley and build upon the strengths of both companies in
manufacturing, packaging and marketing. We anticipate Bentleys vertical
integration with their API manufacturing will provide us with a competitive cost position and bring us significant drugs for the generic prescription market. We believe these drugs could also provide a strong position in the future for Perrigos OTC business as well.

About Bentley
Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on advanced drug delivery technologies and pharmaceutical products.
Bentleys proprietary drug technologies enhance or facilitate the growing portfolio of generic and branded pharmaceuticals in Europe for the treatment of
cardiovascular, gastrointestinal, infections and neurological diseases through its subsidiaries, Laboratorios Belmac, Laboratorios Davur and Laboratorios Rimafar; and manufactures and produces acti ve pharmaceutical ingredients through its subsidiary, Bentley API. Additional information may be obtained through Bentleys web site at;
http://www.bentleypharm.com
http://www.bentleypharm.com/display.asp?navid=0&id=5



CS: BROKERS NOTE: PAGE 10 of 16
Perrigo the store brand sector licensee for TABWRAP

"Perrigo announced in their 2004 US SEC filings that they had encountered a
serious supply problem with one of their suppliers which would impact upon
their revenues. This is believed to be the supplier of their gelatin coated
tablets and, as a result, the licensing agreement with BioProgress has been
executed to provide Perrigo with a non-gelatin replacement tablet coating
technology. The TABWRAP technology will also give Perrigo a significant
competitive advantage for the Peter Black acquisition when competing with
traditional tablet coating suppliers in Europe."

Morning all.

Morning Dave.

Dil i had a nice touch at 80p the other day.

Information requested by Judge at last hearing has now been handed into CC by SEO's lawyers. We will now have to see what transpires.

Does anyone know when we can expect an update regards cc and SEO?
Thanks in advance.....D

Hope you profit from it dave.

85 level breached. Will it hold ???

Yes!

Certainly has, at the moment. Still watching close above 92 or below 85 to confirm next trade. Held those boundaries well over last week.

85 gone to downside, with some decent volume too...

Short at 81

I personally hope anyone shorting this gets burnt...

Why? Only trading it on chart signals. Its what makes a market? Stated my intentions a few days ago.
Any stock that gets so many posts around BB's is bound to be volatile. You have to remember, if you invested in this in July you would be on a 30% profit in a few months, still. Then in the space of 2 months its up 1 from there. Too much too soon.
Nobody is saying its a bad Co. Just a bit ahead of itself.

david 2000-How far down do you think it will go?

Depends on where we close today. If it is below 80p. It looks like 70p is next level of supp/res on long term chart. There is decent volume below 80p at this moment. So the bearish scenario could play out. Hence the short. Have a stop in at breakeven now. With a covering limit order at 72p.
So need to see where we close today really.

Adie, takes 2 to make a market, bit unfair of you to say you hope anyone shorting it gets burnt,dont take it personal, its every man for himself, i know its painfull if your long, ive still got many scars from my crap trades, but its how the cookie crumbles,
David 2000 has posted in a very sensible manner, not been abusive at all,
like he says, its all in the charts,and it is every man to himself in this game

Adie-Ruth is right,I don't short stocks because it frightens the crap out of me but I do look for opportunities to add to existing holdings :-)

Updated old chart... needs to regain 85 really to be bullish, adie. Frightens the crap out of me long or short, e-mail. But just a calculated trade, Risk reward and all that.
Thank you for your kind words Lady Ruth, but me!! sensible :-) You saw me in Harrogate!!

Appreciate all these nice postings about shorting but as you say can be painful if you panic and sell I am long and will continue to hold and top up where I can. The problem I have is that this company is in a much better position than when we touched 1.60 and look at the price... The listing on the nasdaq has not helped short term either. It's very fustrating and I wonder what the board of BPRG think. SEO on the rise and they lost the Court Case... "Glad I am holding both now"... "Dave it's not a personal rant at you - wish I had the access you seem to have to charts etc".